TABLE 3.
Respiratory and medical support needs of pregnant women with mild, moderate or severe COVID‐19 in pregnancy
| Mild | Moderate | Severe | |
|---|---|---|---|
| Total n = 2903 | Total n = 917 | Total n = 616 | |
| Primary reason for hospital admission was COVID‐19 | 625 (29.6) | 617 (77.7) | 474 (82.0) |
| Oxygen saturation measured on admission (Yes) | 1521 (52.5) | 715 (77.5) | 510 (82.8) |
| Median oxygen saturation (IQR) | 98 (97–99) | 96 (94–98) | 96 (93–97) |
| Oxygen saturation <95% | a | 186 (26.0) | 196 (38.4) |
| Evidence of pneumonia on imaging | a | 685 (74.2) | 491 (79.7) |
| Respiratory support required | a | 509 (61.5) | 580 (96.5) |
| Noninvasive oxygen (nasal cannulae, mask or non‐rebreathe mask at <15 L) | a | 479 (100) | 101 (17.9) |
| CPAP or high flow (>15 L) | a | a | 215 (38.1) |
| Invasive ventilation | a | a | 213 (37.7) |
| ECMO | a | a | 36 (6.4) |
| Level not known | a | 30 | 15 |
| Intensive care received | a | a | 529 (85.9) |
| Medical management total b , c | 59 (2.5) | 211 (26.3) | 235 (42.7) |
| Antivirals total c | 8 (0.3) | 21 (2.3) | 70 (11.4) |
| Tocilizumab c | 0 (0) | 5 (0.5) | 55 (8.9) |
| Steroids for maternal indication c | 59 (2.0) | 201 (21.8) | 178 (28.9) |
| Regeneron monoclonal antibodies c | 1 (<0.1) | 3 (0.3) | 2 (0.3) |
| Recruited to the RECOVERY trial | 21 (0.7) | 39 (4.2) | 56 (9.1) |
| Steroids for fetal lung maturation | 280 (10.8) | 164 (22.3) | 312 (57.7) |
Note: All values in n (%).
Abbreviations: CPAP, continuous positive airway pressure; ECMO, extracorporeal membrane oxygenation.
a
Included in definition of groups.
b
Any of the listed medications given for medical management of SARS‐CoV‐2: Antivirals, Tocilizumab, maternal steroids, monoclonal antibodies.
c
Analysis restricted to women admitted on or after July 1, 2020, as guidance on medical management was published in June 2020.